First Trust Advisors LP Chemo Centryx, Inc. Transaction History

First Trust Advisors LP

$101 Billion
Q3 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $1.07 Million - $2.51 Million	48,433 Added 357.65%	61,975 $3.2 Million
Q2 2022 Aug 12, 2022	BUY	$15.36 - $27.51 $208,005 - $372,540	13,542 New	13,542 $336,000
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $320,958 - $1.7 Million	-33,468 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$49.53 - $68.4 $886,834 - $1.22 Million	-17,905 Reduced 34.85%	33,468 $1.72 Million
Q4 2020 Feb 02, 2021	BUY	$47.25 - $65.16 $1.31 Million - $1.8 Million	27,696 Added 116.97%	51,373 $3.18 Million
Q3 2020 Nov 05, 2020	SELL	$46.35 - $61.69 $336,315 - $447,622	-7,256 Reduced 23.46%	23,677 $1.3 Million
Q2 2020 Jul 22, 2020	BUY	$38.58 - $65.07 $1.19 Million - $2.01 Million	30,933 New	30,933 $1.78 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.